PURPOSE: We hypothesized that patients with oropharyngeal cancer treated with intensity modulated proton therapy (IMPT) would have lower symptom burdens, as measured by patient-reported outcome (PRO) surveys, than patients treated with intensity modulated photon therapy (IMRT). METHODS AND MATERIALS: Patients were treated for oropharyngeal cancer from 2006 to 2015 through prospective registries with concurrent chemotherapy and IMPT or chemotherapy and IMRT and completed the MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) module at various times before treatment (baseline), during treatment (acute phase), within the first 3 months after treatment (subacute phase), and afterward (chronic phase). Individual symptoms and the top 5 and top 11 most severe symptoms were summarized and compared between the radiation therapy modalities. RESULTS: PRO data were collected and analyzed from 35 patients treated with chemotherapy and IMPT and from 46 treated with chemotherapy and IMRT. The baseline symptom burdens were similar between both groups. The overall top 5 symptoms were food taste problems (mean score 4.91 on a 0-10 scale), dry mouth (4.49), swallowing/chewing difficulties (4.26), lack of appetite (4.08), and fatigue (4.00). Among the top 11 symptoms, changes in taste and appetite during the subacute and chronic phases favored IMPT (all P<.048). No differences in symptom burden were detected between modalities during the acute and chronic phases by top-11 symptom scoring. During the subacute phase, the mean (±standard deviation) top 5 MDASI scores were 5.15 ± 2.66 for IMPT versus 6.58 ± 1.98 for IMRT (P=.013). CONCLUSIONS: According to the MDASI-HN, symptom burden was lower among the IMPT patients than among the IMRT patients during the subacute recovery phase after treatment. A prospective randomized clinical trial is underway to define the value of IMPT for the management of head and neck tumors.
PURPOSE: We hypothesized that patients with oropharyngeal cancer treated with intensity modulated proton therapy (IMPT) would have lower symptom burdens, as measured by patient-reported outcome (PRO) surveys, than patients treated with intensity modulated photon therapy (IMRT). METHODS AND MATERIALS: Patients were treated for oropharyngeal cancer from 2006 to 2015 through prospective registries with concurrent chemotherapy and IMPT or chemotherapy and IMRT and completed the MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) module at various times before treatment (baseline), during treatment (acute phase), within the first 3 months after treatment (subacute phase), and afterward (chronic phase). Individual symptoms and the top 5 and top 11 most severe symptoms were summarized and compared between the radiation therapy modalities. RESULTS: PRO data were collected and analyzed from 35 patients treated with chemotherapy and IMPT and from 46 treated with chemotherapy and IMRT. The baseline symptom burdens were similar between both groups. The overall top 5 symptoms were food taste problems (mean score 4.91 on a 0-10 scale), dry mouth (4.49), swallowing/chewing difficulties (4.26), lack of appetite (4.08), and fatigue (4.00). Among the top 11 symptoms, changes in taste and appetite during the subacute and chronic phases favored IMPT (all P<.048). No differences in symptom burden were detected between modalities during the acute and chronic phases by top-11 symptom scoring. During the subacute phase, the mean (±standard deviation) top 5 MDASI scores were 5.15 ± 2.66 for IMPT versus 6.58 ± 1.98 for IMRT (P=.013). CONCLUSIONS: According to the MDASI-HN, symptom burden was lower among the IMPTpatients than among the IMRT patients during the subacute recovery phase after treatment. A prospective randomized clinical trial is underway to define the value of IMPT for the management of head and neck tumors.
Authors: David I Rosenthal; Tito R Mendoza; Mark S Chambers; Joshua A Asper; Ibrahima Gning; Merrill S Kies; Randal S Weber; Jan S Lewin; Adam S Garden; K Kian Ang; Xin S Wang; Charles S Cleeland Journal: Head Neck Date: 2007-10 Impact factor: 3.147
Authors: Esengul Kocak-Uzel; G Brandon Gunn; Rivka R Colen; Micheal E Kantor; Abdallah S R Mohamed; Sara Schoultz-Henley; Paniyotis Mavroidis; Steven J Frank; Adam S Garden; Beth M Beadle; William H Morrison; Jack Phan; David I Rosenthal; Clifton D Fuller Journal: Radiother Oncol Date: 2014-04-17 Impact factor: 6.280
Authors: David I Rosenthal; Tito R Mendoza; Mark S Chambers; V Shannon Burkett; Adam S Garden; Amy C Hessell; Jan S Lewin; K Kian Ang; Merrill S Kies; Ibrahima Gning; Xin S Wang; Charles S Cleeland Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-22 Impact factor: 7.038
Authors: Wei Liu; Steven J Frank; Xiaoqiang Li; Yupeng Li; Peter C Park; Lei Dong; X Ronald Zhu; Radhe Mohan Journal: Med Phys Date: 2013-05 Impact factor: 4.071
Authors: Steven J Frank; Pierre Blanchard; J Jack Lee; Erich M Sturgis; Merrill S Kies; Mitchell Machtay; Bhadrasain Vikram; Adam S Garden; David I Rosenthal; G Brandon Gunn; C David Fuller; Katherine Hutcheson; Stephen Lai; Paul M Busse; Nancy Y Lee; Alexander Lin; Robert L Foote Journal: Semin Radiat Oncol Date: 2018-04 Impact factor: 5.934
Authors: Puja Aggarwal; Jhankruti S Zaveri; Ryan P Goepfert; Qiuling Shi; Xianglin L Du; Michael Swartz; G Brandon Gunn; Stephen Y Lai; C David Fuller; Ehab Y Hanna; David I Rosenthal; Jan S Lewin; Linda B Piller; Katherine A Hutcheson Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-11-01 Impact factor: 6.223
Authors: Joseph K Kim; Jonathan E Leeman; Nadeem Riaz; Sean McBride; Chiaojung Jillian Tsai; Nancy Y Lee Journal: Curr Treat Options Oncol Date: 2018-05-09
Authors: William A Hall; Eric S Paulson; Uulke A van der Heide; Clifton D Fuller; B W Raaymakers; Jan J W Lagendijk; X Allen Li; David A Jaffray; Laura A Dawson; Beth Erickson; Marcel Verheij; Kevin J Harrington; Arjun Sahgal; Percy Lee; Parag J Parikh; Michael F Bassetti; Clifford G Robinson; Bruce D Minsky; Ananya Choudhury; Robert J H A Tersteeg; Christopher J Schultz Journal: Eur J Cancer Date: 2019-10-12 Impact factor: 9.162
Authors: Nicolette Taku; Li Wang; Adam S Garden; David I Rosenthal; G Brandon Gunn; William H Morrison; C David Fuller; Jack Phan; Jay P Reddy; Amy C Moreno; Michael T Spiotto; Gregory Chronowski; Shalin J Shah; Lauren L Mayo; Neil D Gross; Renata Ferrarotto; X Ronald Zhu; Xiaodong Zhang; Steven J Frank Journal: Curr Treat Options Oncol Date: 2021-06-04
Authors: Sonja Stieb; Grete M Engeseth; Abdallah S R Mohamed; Renjie He; Ismael Perez-Martinez; Stockton Rock; Tanaya S Deshpande; Adam S Garden; David I Rosenthal; Steven J Frank; G Brandon Gunn; C David Fuller Journal: Acta Oncol Date: 2022-01-21 Impact factor: 4.089